LEF1 and cancer: Interestingly, we found that patient CML-6 had the best clinical response to imatinib and was able to achieve a complete cytogenetic response (CCR) within seven months of initiating therapy; LEF-1 expression was markedly inhibited by imatinib in this cancer.